about
Evolutionarily repurposed networks reveal the well-known antifungal drug thiabendazole to be a novel vascular disrupting agentNeutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor modelDevelopment of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinasesA novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cellsRandomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancerVascular disrupting action of electroporation and electrochemotherapy with bleomycin in murine sarcoma.The Role of RhoJ in Endothelial Cell Biology and Tumor PathologyTumor resistance to vascular disrupting agents: mechanisms, imaging, and solutionsThe use of dynamic nuclear polarization (13)C-pyruvate MRS in cancerVasculogenesis: a crucial player in the resistance of solid tumours to radiotherapyMultiscale modelling of vascular tumour growth in 3D: the roles of domain size and boundary conditionsQuantitative ex-vivo micro-computed tomographic imaging of blood vessels and necrotic regions within tumors.Differential mechanisms associated with vascular disrupting action of electrochemotherapy: intravital microscopy on the level of single normal and tumor blood vesselsMicrotubule-binding agents: a dynamic field of cancer therapeutics.Antivascular and antitumor properties of the tubulin-binding chalcone TUB091Eribulin in the management of inoperable soft-tissue sarcoma: patient selection and survivalCurrent Advances of Tubulin Inhibitors in Nanoparticle Drug Delivery and Vascular Disruption/AngiogenesisNovel surface targets and serum biomarkers from the ovarian cancer vasculatureAntibody drug-conjugates targeting the tumor vasculature: Current and future developmentsVascular disrupting agent drug classes differ in effects on the cytoskeletonTubulin-destabilizing agent BPR0L075 induces vascular-disruption in human breast cancer mammary fat pad xenograftsAntitumor effects of combining docetaxel (taxotere) with the antivascular action of ultrasound stimulated microbubblesA combretastatin-mediated decrease in neutrophil concentration in peripheral blood and the impact on the anti-tumor activity of this drug in two different murine tumor modelsSuprafenacine, an indazole-hydrazide agent, targets cancer cells through microtubule destabilizationEnhanced antitumor efficacy of a vascular disrupting agent combined with an antiangiogenic in a rat liver tumor model evaluated by multiparametric MRITumor angiogenesisEnhancing Tumor Penetration of Nanomedicines.Combining vasculature disrupting agent and Toll-like receptor 7/8 agonist for cancer therapy.Multimodal imaging guided preclinical trials of vascular targeting in prostate cancer.The anti-tumor agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), induces IFN-beta-mediated antiviral activity in vitro and in vivo.Using semi-quantitative dynamic contrast-enhanced magnetic resonance imaging parameters to evaluate tumor hypoxia: a preclinical feasibility study in a maxillofacial VX2 rabbit modelMonitoring antivascular therapy in head and neck cancer xenografts using contrast-enhanced MR and US imagingTumor radiation response enhancement by acoustical stimulation of the vasculature.Thrombospondin 1 and vasoactive agents indirectly alter tumor blood flow.Ultrasonically targeted delivery into endothelial and smooth muscle cells in ex vivo arteries.Three-dimensional analysis of tumour vascular corrosion casts using stereoimaging and micro-computed tomographyTumour biomechanical response to the vascular disrupting agent ZD6126 in vivo assessed by magnetic resonance elastographyDiscovery of 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties.The response of RIF-1 fibrosarcomas to the vascular-disrupting agent ZD6126 assessed by in vivo and ex vivo 1H magnetic resonance spectroscopy.Anti-vascular agent Combretastatin A-4-P modulates hypoxia inducible factor-1 and gene expression.
P2860
Q21145736-9E4E8474-1E4D-4950-B74B-CC20628FB2C1Q24612339-E56432EF-4F7C-4AE8-A3FE-A1AEE35CC1F9Q24617675-96A77ECE-39A5-4AEE-8670-EFFDA7026749Q24622083-974904EE-4E2A-4695-B9BE-D0DD736613D6Q24642049-DF047F5E-108A-4CE4-A67D-FD2EFBF150A7Q24651349-94DD03D2-07A2-47AE-A1C7-5E4D930ED6C7Q26739169-6E5CEB14-8F61-4CB2-AE7C-1C111A7AF396Q26774355-057B1BD5-0E16-4190-80CC-18BFA8103474Q26778444-7DE78F2B-15C3-4DF9-9FF4-1A81ECB5989FQ26999217-F4E13BD3-11F5-4719-B357-DFD36DE11257Q27313831-732C5D78-4DEF-4921-886A-02D7F2A6DD2EQ27330382-AB03EEEE-8502-4FA3-AF81-5F94E2F83D1BQ27333617-5C0DAD0E-EDB9-4ED8-AE39-A70956703E94Q27690249-D66BD35D-3156-46B1-AF33-AEEBE00F9D38Q27705273-B2E3E3AD-E276-4976-A75F-F8A9D4786766Q28074125-C751C0D9-D299-48EA-B872-70FD95BF1122Q28077780-278991DB-0E2A-4176-995D-F5CC3B81136CQ28238739-5B8B8C0E-49DC-4AEC-A4FB-0A041EBE743AQ28270261-F3400ADC-7F07-46E6-9A4D-A3B7785CCE1BQ28481498-FCC646E4-5482-4046-8E98-1FD678E76E55Q28482576-B49D8B04-E10B-4FA2-B00B-A1DF428EB998Q28484485-AF809AA1-8DC6-49EC-8411-71F563C44B21Q28543671-6EE719C2-11AC-462D-A481-E1AA07CE208DQ28544463-103490E2-691E-40B0-864A-0A8DD217E98AQ28729080-45F1F792-FF83-4829-9B11-34FDD998B478Q29614938-B452847E-372C-4FEC-8B65-2158562A09A1Q30356887-73DEED85-B681-4795-A4A9-FF665E245C0DQ30358185-1CF3142B-1638-4D1A-B20A-0A4DE3704046Q30393012-1F437CAD-68A3-4F39-A8F5-7FC79FD873BAQ30396361-3DF5BE4F-3225-43F4-AA2E-489722B10DB4Q30409908-64D582BD-9327-4346-B509-477B4AC5427DQ30452632-C94C6A1F-85A0-4668-A522-82136E171156Q30458925-E66AFD77-8B3F-4DF2-8124-532E5E93E41AQ30482804-F7DA20A4-04D3-4379-8526-317253F99A3AQ30544301-B5F4B502-736F-4A26-8B60-B2CAECD80D95Q30640206-7CDDADC4-CF46-42CB-AE86-3B47A694D590Q30764503-024643F5-5288-439B-9A47-DB08A25CC671Q31024172-F5A0FE22-50BB-4C76-874D-44D4582FAA81Q31049713-3FE789B2-6D8B-4AF4-A23C-27F0ED731D7AQ33265941-2E735B84-41DE-4447-AC79-735BBC6B4205
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Disrupting tumour blood vessels.
@ast
Disrupting tumour blood vessels.
@en
type
label
Disrupting tumour blood vessels.
@ast
Disrupting tumour blood vessels.
@en
prefLabel
Disrupting tumour blood vessels.
@ast
Disrupting tumour blood vessels.
@en
P2093
P356
P1476
Disrupting tumour blood vessels.
@en
P2093
Bruce C Baguley
Chryso Kanthou
Gillian M Tozer
P2888
P304
P356
10.1038/NRC1628
P407
P577
2005-06-01T00:00:00Z
P5875
P6179
1017276673